120
Participants
Start Date
May 30, 2017
Primary Completion Date
June 28, 2021
Study Completion Date
May 30, 2022
ANAKINRA 100 mg/daily subcutaneously
ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Placebo
PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
ACTION Study Group - Department of Cardiology - Pitié Salpétrière Hospital, 47 Bd de l'Hopital, Paris
Department of internal medicine - Pitié Salpétrière Hospital, 47 Bd de l'Hopital, Paris
Assistance Publique - Hôpitaux de Paris
OTHER